| |
| Metabolic Syndrome Institute at the World Congress of Cardiology |
 Dear MSI Newsletters Readers,
We are happy to announce that the Metabolic Syndrome Institute will hold a scientific session at the World Congress of Cardiology in Buenos Aires (Argentina) on Monday, the 19th of May, between 10:30 am and 12:00 pm.
Please find below the enclosed Program of the MSI session, its topic being "The Metabolic Syndrome: Growing Prevalence in Latin America and Treatment". You may also find the complete scientific program of the WCC by following this link: http://www.worldcardiocongress.org
If you attend this important event, please note that the Metabolic Syndrome Institute will also have a booth (n°264), where we will be happy to welcome you and present you the last updates of the MSI website: http://www.metabolic-syndrome-institute.org
We hope we will have the pleasure to see you in Buenos Aires.
The MSI special session at WCC
The Metabolic Syndrome: Growing Prevalence in Latin America and Treatment
Chairs: Carlos Romero / Dr. Pineiro
Monday, 19th of May,
10:30am-12:00pm
Parana Room, Ochre Pavillion,
La Rural Convention and Exhibition Centre
in Buenos Aires
|
10:30-10:47am
The Emerging Obesity Problem in Latin America
Ada Cuevas, MD
Chile
10:47–10:52am
DISCUSSION
10:52-11:09am
Drug Therapy for the Dyslipidemia of the Metabolic Syndrome
Jean-Charles Fruchart, PhD
France
11:09-11:14am
DISCUSSION
|
11:14-11:31am
The Metabolic Syndrome as a Risk Factor for Diabetes
TBD
11:31-11:36am
DISCUSSION
11:36-11:53am
The Metabolic Syndrome as a Risk Factor for
Cardiovascular Disease
Scott Grundy, MD, PhD
USA
11:53-11:58am
DISCUSSION
|
|
|
Metabolic Syndrome News
(from April 2008)
|
| Epidemiology |
A genotype score of nine validated single-nucleotide polymorphisms as an independent risk factor for incident cardiovascular disease
(Posted April 30, 2008) | View
Central obesity in midlife increases risk of dementia independently of diabetes and cardiovascular comorbidities
(Posted April 28, 2008) | View
A population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome in Lausanne
(Posted April 25, 2008) | View
Metabolic syndrome as an important health problem among the adult population of Trabzon, Turkey
(Posted April 22, 2008) | View
Calcium intake negatively related to body fat and insulin resistance in post-pubertal obese girls
(Posted April 21, 2008) | View
Association between age at menarche and risk of diabetes: results from the EPIC-Norfolk cohort
(Posted April 15, 2008) | View
Waist circumference prospectively linked to colon cancer risk
(Posted April 14, 2008) | View
The metabolic syndrome as predictor of incident stroke
(Posted April 10, 2008) | View
Effects of dietary carbohydrate, glycaemic index and glycaemic load on the risk of metabolic syndrome in a Korean population
(Posted April 9, 2008) | View
Prevalence of metabolic syndrome in the Jackson Heart Study among the highest for population-based cohorts worldwide
(Posted April 8, 2008) | View
Psoriasis associated with diabetes in a population-based cross-sectional study
(Posted April 7, 2008) | View
An association between psoriasis and metabolic syndrome in a cross-sectional case-control study
(Posted April 4, 2008) | View
Hypertensive patients who develop diabetes mellitus are at higher risk of atrial fibrillation and heart failure
(Posted April 1, 2008) | View
|
| |
| Screening & Diagnosis |
|
Insulin as the only reliable biomarker to differentiate metabolic syndrome status in an obese population with elevated waist circumference
(Posted April 23, 2008) | View
Including abnormal liver function tests in the definition of metabolic syndrome could increase its predictive nature for cardiovascular disease
(Posted April 17, 2008) | View
Gender differences in the response to the oral glucose tolerance test may be accounted for by height
(Posted April 3, 2008) | View
The triglyceride to high-density lipoprotein cholesterol ratio may be a clinically useful indicator for hyperinsulinaemia among nondiabetic adults regardless of race/ethnicity
(Posted April 2, 2008) | View
|
| |
| Pathophysiological Aspects |
|
The term metabolic syndrome does not adequately describe the effects of GnRH agonists in men with prostate cancer
(Posted April 16, 2008) | View
|
| |
|
Metabolic Syndrome Components / Risk Factors / Associated Risks
|
|
(Abdominal Obesity)
Abdominal adiposity in women strongly associated with all-cause, cardiovascular, and cancer mortality independently of body mass index
(Posted April 29, 2008) | View
|
| |
| Prevention and Treatment |
Laparoscopic ileal interposition associated with sleeve gastrectomy for the control of metabolic syndrome in patients with type 2 diabetes
(Posted April 18, 2008) | View
The weight loss maintenance randomized controlled trial
(Posted April 11, 2008) | View
|
|
|
Featured Upcoming Congresses
(May - November 2008)
|
| 16th European Congress on Obesity (ECO) |
|
Date:
|
|
May 14-17, 2008 |
|
Location:
|
|
Geneva, Switzerland |
|
Website:
|
|
http://www.eco2008.org/ |
| |
| AACe 17th Annual Meeting and Clinical Congress |
|
Date:
|
|
May 14-18, 2008 |
|
Location:
|
|
Orlando, Florida, USA |
|
Website:
|
|
http://www.aace.com |
| |
|
5th World Congress on Prevention of Diabetes and its Complications
|
|
Date:
|
|
June 1-4, 2008 |
|
Location:
|
|
Helsinki, Finland |
|
Website:
|
|
http://www.diabetes.fi/index.php?lk_id=57 |
|
|
| 3rd International Symposium on Integrated Biomarkers in Cardiovascular Disease |
|
Date:
|
|
July 9-11, 2008 |
|
Location:
|
|
Seattle, WA |
|
Website:
|
|
http://www.ibcvd.org/home.aspx |
| |
| Australian Diabetes Society / ADEA Annual Scientific Meeting |
|
Date:
|
|
August 28-30, 2008 |
|
Location:
|
|
Melbourne, Australia |
|
Website:
|
|
http://www.racp.edu.au/ads/meetings.htm |
| |
| ESC Congress 2008 |
|
Date:
|
|
August 30-September 3, 2008 |
|
Location:
|
|
Munich, Germany |
|
Website:
|
|
http://www.escardio.org |
| |
| 2008 Cardiometabolic Health Congress |
|
Date:
|
|
October 15-18, 2008 |
|
Location:
|
|
Boston, MA |
|
Website:
|
|
http://www.cardiometabolichealth.org/
|
| |
| 1st Diabetes in Asia Study Group Conference |
|
Date:
|
|
October 16-19, 2008 |
|
Location:
|
|
Kathmandu, Nepal |
|
Website:
|
|
http://dasg.dapkhi.org/Default.aspx |
| |
| 2nd World Congress on Controversies in Diabetes, Obesity and hypertension (CODHy) |
|
Date:
|
|
October 30-November 2, 2008 |
|
Location:
|
|
Barcelona, Spain |
|
Website:
|
|
http://www.codhy.com/codhy2/ |
| |
| > View all upcoming congresses |
|
|
Download the MSI Slide Kit
Slide Kit part 1:
The Main Threat To Human Health For The Next Decade
Slide Kit part 2:
The Double Jeopardy of the Metabolic Syndrome
Slide Kit part 3:
Defusing the Metabolic Time Bomb
Slide Kit part 4:
Combating the Metabolic Syndrome: Action Plan
Slide Kit part 5:
Metabolic Syndrome and Insulin Resistance
Slide Kit part 6:
A Reversible Life-Threatening Condition
|
Ongoing Trials With Lipid-Modifying Agents
(Prevention of Cardiovascular Events)
Trial - CORONA
Crestor Versus Placebo in Subjects with Heart Failure
Outcome: Combined endpoint of cardiovascular death or non-fatal myocardial infarction or non-fatal stroke (time to first event)
Expected total enrollment: 5013 patients with chronic symptomatic systolic heart failure (of ischaemic aetiology) and with optimal therapy for this condition.
Comparisons: Rosuvastatin vs placebo.
Design: Randomized, double-blind, placebo control, parallel assignment.
Trial - ARISE
Agressive Reduction of Inflammation Stops Events
Outcome: Length of time to the first occurrence of one of six adjudicated events: cardiovascular mortality, resuscitated cardiac arrest, non-fatal MI, non-fatal stroke. hospitalization for angina pectoris, or use of coronary revascularization
Expected number of patients:
6000 patients with acute MI or unstable angina > 14 days and ≤ 1 year prior to randomization, and either with diabetes mellitus (type 2 or type 1), or ≥ 55 years and with one additional risk factor [(i) ≥ 60 years; (ii) low HDL-C: <40 mg/dL for men and <50mg/dL for women; (iii) previous MI (in addition to the index event), or diagnosis of atherosclerosis in a non-coronary vessel (e.g. history of prior stroke, presence of peripheral vascular disease); (iv) prior history of congestive heart failure or ejection fraction <40%].
Comparisons: Probucol analog vs placebo.
Design: Randomized, double-blind, placebo control, parallel assignment.
> View all landmark studies and clinical trials
|
Framingham Risk Assessment Tool
Estimates 10-year risk of developing hard CHD
> View Tool
Procam Risk Calculator
Estimates your risk of a heart attack (myocardial infarction) within the next 10 years based upon data of the PROCAM Study
> View Calculator
SCORE
(European High Risk Chart)
Estimates 10 year risk of fatal CVD in high risk regions of Europe by gender, age, systolic blood pressure, total cholesterol and smoking status.
> View Chart
UKPDS Risk Engine
The UKPDS Risk Engine is a type 2 diabetes specific risk calculator based on 53,000 patients years of data from the UK Prospective Diabetes Study, which also provides an approximate 'margin of error' for each estimate.
> View Risk Engine
|
Mission of the Metabolic
Syndrome Institute |
|
Created in 2003, the Metabolic Syndrome Institute is an independent and not for profit association. Its members are international experts in lipid metabolism, diabetes, heart disease, endocrinology obesity, genetics, epidemiology, basic research and health economics. Being the first association totally devoted to the dissemination of knowledge about the metabolic syndrome, the Metabolic Syndrome Institute will provide an international multidisciplinary approach to a worldwide public health problem.
|
| |
|
Contact Metabolic Syndrome Institute
|
212, avenue Paul Doumer
92500 Rueil-Malmaison Cedex
FRANCE
Phone: (33) 1 41 42 20 35
Fax: (33) 1 41 42 20 01
Email:
contact@metabolic-syndrome-institute.org
Website:
http://www.metabolic- syndrome-institute.org |
|
